<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">PHENAZOPYRIDINE HYDROCHLORIDE</span><br/>(fen-az-oh-peer'i-deen)<br/><span class="topboxtradename">Azo-Standard, </span><span class="topboxtradename">Baridium, </span><span class="topboxtradename">Geridium, </span><span class="topboxtradename">Phenazo <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Phenazodine, </span><span class="topboxtradename">Pyridiate, </span><span class="topboxtradename">Pyridium, </span><span class="topboxtradename">Pyronium <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Urodine, </span><span class="topboxtradename">Urogesic<br/></span><b>Classifications:</b> <span class="classification">urinary tract analgesic</span><br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>95 mg, 97.2 mg, 100 mg, 150 mg, 200 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Azo dye. Precise mechanism of action not known.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Local anesthetic action on urinary tract mucosa which imparts little or no antibacterial activity.</p>
<h1><a name="uses">Uses</a></h1>
<p>Symptomatic relief of pain, burning, frequency, and urgency arising from irritation of urinary tract mucosa, as from infection,
         trauma, surgery, or instrumentation.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Renal insufficiency, glomerulonephritis, pyelonephritis during pregnancy (category B); severe hepatitis.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>GI disturbances; glucose-6-phosphate dehydrogenase deficiency, lactation.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Cystitis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 200 mg t.i.d.<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 12 mg/kg/d in 3 divided doses<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with or after meals.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Headache, vertigo. <span class="typehead">GI:</span> Mild GI disturbances. <span class="typehead">Urogenital:</span> Kidney stones, transient acute kidney failure. <span class="typehead">Metabolic:</span> Methemoglobinemia, hemolytic anemia. <span class="typehead">Skin:</span> Skin pigmentation. <span class="typehead">Special Senses:</span> May stain soft contact lenses. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Phenazopyridine may interfere with any urinary test that is based on color reactions or spectrometry: <span class="alt">bromsulphalein</span> and <span class="alt">phenolsulfonphthalein</span> excretion tests; urinary <span class="alt">glucose</span> test using <span class="alt">Clinistix</span> or <span class="alt">TesTape</span> (<span class="alt">copper-reduction methods</span> such as <span class="alt">Clinitest</span> and <span class="alt">Benedict's test</span> reportedly not affected); <span class="alt">bilirubin</span> using "foam test" or <span class="alt">Ictotest;</span> <span class="alt">ketones</span> using <span class="alt">nitroprusside</span> (e.g., <span class="alt">Acetest,</span> <span class="alt">Ketostix,</span> or <span class="alt">Gerhardt ferric chloride</span>); <span class="alt">urinary protein</span> using <span class="alt">Albustix,</span> <span class="alt">Albutest,</span> or <span class="alt">nitric acid ring test;</span> urinary <span class="alt">steroids;</span> <span class="alt">urobilinogen;</span> <span class="alt">assays</span> for <span class="alt">porphyrins.</span>
</p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> No clinically significant interactions established. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Distribution:</span> Crosses placenta in trace amounts. <span class="typehead">Metabolism:</span> Metabolized in liver and other tissues. <span class="typehead">Elimination:</span> Primarily excreted in urine. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Obtain periodic blood work and kidney function tests in patients on prolonged therapy or with impaired kidney function.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Be aware that drug will impart an orange to red color to urine and may stain fabric.</li>
<li>Discontinue drug report to physician immediately the appearance of yellowish tinge to skin or sclerae may indicate drug accumulation
            due to renal impairment.
         </li>
<li>Discontinue drug when pain and discomfort are relieved (usually 315 d). Keep physician informed.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>